negative breast tnb cancer cell line hcc1806 (ATCC)
Structured Review

Negative Breast Tnb Cancer Cell Line Hcc1806, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 963 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/negative breast tnb cancer cell line hcc1806/product/ATCC
Average 97 stars, based on 963 article reviews
Images
1) Product Images from "Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth"
Article Title: Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth
Journal: Signal Transduction and Targeted Therapy
doi: 10.1038/s41392-026-02650-3
Figure Legend Snippet: Determination of anti-tumor activity of iMac with induced ACE expression, in vitro. a Proliferation of melanoma (SK-MEL-28), Triple Negative Breast Cancer (TNBC: HCC1806), and FP chemotherapy resistant HNSCC (FaDu/FP-R) cell lines cultured alone or indirectly co-cultured with iMac ( ± Dox) using 3.0 µm pore polyester membrane inserts for 5 days. Total and dead cell counts were determined via trypan blue exclusion on days 1, 3, and 5. b , c Quantification of iNOS and interleukin-12 (IL-12) production in Cnt-iMac and ACE-iMac treated with LPS (500 ng/ml, 12 h), ± Dox. d ROS production in ACE-iMac following LPS stimulation (1 µg/ml, 30 min) ±Dox, assessed by DCFDA (2’,7’-dichlorodihydrofluorescein diacetate) staining. Representative histograms (left) and mean fluorescence intensity (MFI) quantification (right) are shown. Nitric Oxide (NO) production in ACE-iMac stimulated with LPS (75 ng/ml) for 24 h ( e ), and/or conditioned with SK-MEL-28 supernatant for 24 h ( f ) ± Dox. g Perforin and IFN-γ levels in human peripheral blood NK and Tc cells, respectively, after co-culture with Cnt-iMac or ACE-iMac pretreated with LPS (24 h), followed by melanoma conditioning (24 h). To induce ACE expression, myeloid progenitors were differentiated in the presence of Dox and maintained at 1 µg/ml throughout all in vitro assays. Experiments were performed in triplicates across three independent replicates. Statistical analyses included one-way ANOVA ( a ), two-way ANOVA with Bonferroni correction ( b , c , g ), and two-sided unpaired Student’s t -test ( d – f ). Data are presented as means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001
Techniques Used: Activity Assay, Expressing, In Vitro, Cell Culture, Membrane, Staining, Fluorescence, Co-Culture Assay
Figure Legend Snippet: The effect of ACE-expressing iMac treatment on tumor growth in immunocompromised nude mice. To induce ACE expression, myeloid progenitors were differentiated in the presence of 1 µg/ml Dox (termed as ACE-iMac), while control iMac with basal ACE expression were differentiated in the absence of Dox. a Experimental scheme of iMac treatment. Mice were injected intratumorally with PBS, Cnt-iMac (±Dox) or ACE-iMac (±Dox) weekly (3–4 doses) as indicated by arrow. b Growth of melanoma xenografts derived from the SK-MEL-28 cell line. c Growth of breast cancer xenografts derived from the HCC1806 cell line. d Growth of HNSCC xenografts derived from the FaDu/FP-R cell line. For b – d Left panels show plots comparing tumor growth rates, the middle panels show representative images of tumors, and right panels show graphs comparing tumor weight. Following cell administration, Dox+ (ACE-iMac) mouse groups were provided with 150 µg/ml doxycycline in their drinking water throughout the duration of the study. Group comparisons were analyzed using one-way ANOVA with Bonferroni’s correction for multiple comparisons. Data are presented as means ± SEM ( n = 5–10). * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001
Techniques Used: Expressing, Control, Injection, Derivative Assay